How Bayer is building a cell and gene therapy business through deals

After spending the last year laying the groundwork for its entrance into cell and gene therapies through dealmaking, Bayer is expanding its external innovation search to new indications and earlier-stage programs and technologies to build off that foundation.

Bayer AG (Xetra:BAYN) signed over 25 deals last year — a major ramp-up from previous years — spanning research collaborations to acquisitions, as well as equity investments through its Leaps by Bayer corporate venture arm. ...